A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin.
10.1007/s11596-016-1610-y
- Author:
Zhi-Kang YE
1
;
Ken CHEN
1
;
Yao-Long CHEN
2
;
Suo-di ZHAI
3
Author Information
1. Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China.
2. Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Gansu, 730000, China.
3. Department of Pharmacy, Peking University Third Hospital, Beijing, 100191, China. zhaisuodi@163.com.
- Publication Type:Journal Article
- Keywords:
Development and Evaluation;
Grade of Recommendations Assessment;
guideline;
therapeutic drug monitoring;
vancomycin
- MeSH:
Anti-Bacterial Agents;
administration & dosage;
economics;
pharmacokinetics;
China;
Drug Administration Schedule;
Drug Monitoring;
methods;
Evidence-Based Medicine;
Humans;
Methicillin-Resistant Staphylococcus aureus;
drug effects;
growth & development;
pathogenicity;
Staphylococcal Infections;
drug therapy;
microbiology;
pathology;
Vancomycin;
administration & dosage;
economics;
pharmacokinetics
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2016;36(3):469-472
- CountryChina
- Language:English
-
Abstract:
This study aimed to develop a guideline for therapeutic drug monitoring (TDM) of vancomycin. We adopted the new guideline definition from the Institute of Medicine (IOM), adhered closely to the six domains of the Appraisal of Guidelines for Research & Evaluation II (AGREE II), and made recommendations based on systematic reviews. We established a Guideline Steering Group and a Guideline Development Group, formulated 12 questions in the form of Population, Intervention, Comparison, Outcome (PICO) and completed a literature search. As far as we know, we will develop the first evidenced-based guideline for vancomycin TDM under the framework of the Grade of Recommendations Assessment, Development and Evaluation (GRADE).
